This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed PubMed Citation Articles by SoRelle, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHLORTHALIDONE DOXAZOSIN MESYLATE Medline Plus Health Information Cholesterol Heart Attack Heart Failure High Blood Pressure

(Circulation. 2000;101:e9025.)
© 2000 American Heart Association, Inc.

Cardiovascular News

National Heart, Lung, and Blood Institute Halts Part of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Ruth SoRelle, MPH Circulation Newswriter

The National Heart, Lung, and Blood Institute (NHLBI) halted one part of the large ALLHAT high blood pressure study because one of the drugs, an -adrenergic blocker, was found to be less effective than the traditional diuretic in reducing some forms of heart disease (http://www.nhlbi.nih.gov/new/press/mar08-00.htm).

The ALLHAT study was designed to have 2 parts. One compared newer drug treatments for high blood pressure with more conventional and less costly treatment. The other compared treatments for high cholesterol.

The -adrenergic blocker was doxazosin, and the diuretic was chlorthalidone. In the study, those who took doxazosin had 25% more cardiovascular events and were twice as likely to be hospitalized for congestive heart failure as those who used chlorthalidone. The drugs had similar rates of effectiveness in preventing heart attacks and in reducing the risk of deaths from all causes.

The federal agency took the action only after an independent data review by a committee specifically set up to do such monitoring was completed. Patients who were taking doxazosin were offered an alternative medication in consultation with their personal physicians.

"This finding adds important information to our understanding of antihypertensive drugs," said NHLBI Director Dr Claude Lenfant, MD. "No large-scale blood pressure treatment study had ever compared these 2 classes of drugs. Earlier studies were small and could not, for example, detect an increase in patients’ risk of congestive heart failure."

The other part of the ALLHAT study dealing with high cholesterol will continue until 2002, the time when the study was expected . . . [Full Text of this Article]